Share

分享

Facebook

脸书

Twitter

推特

LinkedIn

LinkedIn

Email this page

通过电子邮件发送此页面

Natarajan Sethuraman, PhD

Natarajan Sethuraman博士

President of Research and Development

研发总裁

BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines. Today, the Company announced that Natarajan Sethuraman, PhD, currently its Chief Scientific Officer, has been promoted to President of Research and Development, effective immediately.

波士顿，2024年9月24日（环球通讯社）--Entrada Therapeutics，Inc.（纳斯达克：TRDA）是一家临床阶段的生物制药公司，旨在通过建立细胞内内体逃逸载体（EEV™）来改变患者的生活。治疗作为一类新的药物。今天，该公司宣布，现任首席科学官Natarajan Sethuraman博士已晋升为研发总裁，立即生效。

“Natarajan has been with Entrada since our inception and his leadership has been invaluable in the research and clinical development of the company’s diverse pipeline of proprietary intracellular therapeutics,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. “His deep and broad experience in end-to-end therapeutics development has helped advance our ENTR-601-44 program into the clinic, build our pipeline, and establish a dedicated team driven by intellectual curiosity, teamwork and a commitment to patients and their families.” 'From the moment I joined Entrada, I have been excited by the versatility of our differentiated approach to intracellular therapeutics, and the potential to reach targets that have long been considered inaccessible,” said Dr.

Entrada therapeutics首席执行官迪帕尔·多西（DipalDoshi）表示：“自我们成立以来，纳塔拉扬一直在Entrada工作，他的领导在该公司多种专有细胞内治疗药物的研究和临床开发中发挥着不可估量的作用。”。“他在端到端治疗开发方面的丰富经验有助于将我们的ENTR-601-44项目推进临床，建立我们的管道，并建立一个由好奇心，团队合作和对患者及其家人的承诺驱动的专门团队。”“从我加入Entrada的那一刻起，我就对我们对细胞内治疗的差异化方法的多功能性以及达到长期以来被认为无法实现的目标的潜力感到兴奋，”Dr。

Sethuraman. “I am tremendously proud of the amazing progress of our team and look forward to advancing our clinical pipeline to positively impact the lives of patients and their families.' Dr. Sethuraman joined Entrada Therapeutics as Chief Scientific Officer in 2017 and leads global research and clinical development.

塞图拉曼。“我为我们团队取得的惊人进展感到无比自豪，并期待着推进我们的临床渠道，以积极影响患者及其家人的生活。”Sethuraman博士于2017年加入Entrada Therapeutics担任首席科学官，领导全球研究和临床开发。

He brings deep experience in drug discovery and development across multiple modalities including oligonucleotides, antibodies, therapeutic enzymes, and peptides. Under his leadership, Entrada has built an R&D team that is advancing an exp.

他在药物发现和开发方面拥有丰富的经验，包括寡核苷酸，抗体，治疗酶和肽。在他的领导下，恩特拉达建立了一个研发团队，正在推进一项实验。